China Pushes for Parrot Fever Vaccine as Human Cases Surge
Listen to the full version
China’s Ministry of Agriculture and Rural Affairs has added the vaccine for parrot fever to a new directory of critically needed and locally undersupplied veterinary drugs, aiming to spur domestic development as human infections jump.
The ministry’s Center for Veterinary Drug Evaluation said the directory was established to drive innovation in the veterinary pharmaceutical industry and address supply bottlenecks for essential pet medications. Following targeted research and extensive consultations with clinical experts, the center compiled the list to serve as a roadmap for drug developers.
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Save an extra $50. Introductory offer for new readers. Subscribe now.
- DIGEST HUB
Digest Hub
Back
- China added a parrot fever vaccine to a critical veterinary drug directory to boost domestic development as human infections rise.
- Monthly human caseloads have increased since 2023; the CDC recommends making the disease legally notifiable.
- No approved vaccine exists for pet birds, and uptake of existing chicken vaccines remains low.
- Beijing Huaxin Nongwei Biotechnology Co.
- Beijing Huaxin Nongwei Biotechnology Co. produces China's only approved avian chlamydia vaccine—a genetically engineered subunit vaccine for chickens. General manager Zhang Lianxiang noted low farmer uptake because parrot fever mainly affects egg yield and hatch rates, unlike fatal bird flu.
- 2023 (current context)：
- The Ministry of Agriculture and Rural Affairs added a vaccine for parrot fever to a new directory of critically needed and locally undersupplied veterinary drugs, aiming to spur domestic development amid rising human infections. The directory was established following targeted research and consultations with clinical experts.
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新